Context Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Context Therapeutics Current Ratio Growth & History (CNTX)
Context Therapeutics's current ratio was 8.52 for fiscal 2025.
View full Context Therapeutics company overviewContext Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 8.52 | −27.10 | −76.07% |
| 2024 | 2024-12-31 | 35.62 | 31.79 | +830.40% |
| 2023 | 2023-12-31 | 3.83 | −7.97 | −67.56% |
| 2022 | 2022-12-31 | 11.80 | −5.10 | −30.16% |
| 2021 | 2021-12-31 | 16.90 | 16.87 | +53796.35% |
| 2020 | 2020-12-31 | 0.03 | — | — |
Context Therapeutics quarterly current ratio
Q4.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.81 | −13.28 | −69.55% |
| Q1 2026 | 2026-03-31 | 8.96 | −39.85 | −81.65% |
| Q4 2025 | 2025-12-31 | 8.52 | −27.10 | −76.07% |
| Q3 2025 | 2025-09-30 | 13.10 | −23.81 | −64.51% |
| Q2 2025 | 2025-06-30 | 19.09 | −44.93 | −70.18% |
| Q1 2025 | 2025-03-31 | 48.80 | 44.57 | +1053.17% |
| Q4 2024 | 2024-12-31 | 35.62 | 31.79 | +830.40% |
| Q3 2024 | 2024-09-30 | 36.91 | 31.92 | +639.71% |
| Q2 2024 | 2024-06-30 | 64.01 | 56.64 | +768.03% |
| Q1 2024 | 2024-03-31 | 4.23 | −5.63 | −57.09% |
| Q4 2023 | 2023-12-31 | 3.83 | −7.97 | −67.56% |
| Q3 2023 | 2023-09-30 | 4.99 | −5.47 | −52.28% |
| Q2 2023 | 2023-06-30 | 7.37 | −7.27 | −49.63% |
| Q1 2023 | 2023-03-31 | 9.86 | −19.30 | −66.19% |
| Q4 2022 | 2022-12-31 | 11.80 | −5.10 | −30.16% |
| Q3 2022 | 2022-09-30 | 10.45 | 10.36 | +10434.29% |
| Q2 2022 | 2022-06-30 | 14.64 | — | — |
| Q1 2022 | 2022-03-31 | 29.16 | — | — |
| Q4 2021 | 2021-12-31 | 16.90 | 16.87 | +53796.35% |
| Q3 2021 | 2021-09-30 | 0.10 | — | — |
| Q4 2020 | 2020-12-31 | 0.03 | — | — |
Context Therapeutics current ratio trends
Over the last five fiscal years, Context Therapeutics's current ratio increased from 0.03 to 8.52, a change of 8.49. The latest reported quarter, Q2 2026, shows 5.81.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Context Therapeutics source filings ↗